Diffusion Pharmaceuticals Inc. — Q3 2016 Form 10-Q
Filing identity: The supplied filing is for Diffusion Pharmaceuticals Inc., not Cervomed Inc. It covers the unaudited quarter and nine months ended September 30, 2016.
Business context and reporting period
Diffusion is a clinical-stage biotechnology company developing trans sodium crocetinate (TSC), intended to improve the effectiveness of radiation and chemotherapy by increasing oxygenation in tumors. The January 8, 2016 merger with Diffusion Pharmaceuticals LLC was accounted for as a reverse acquisition; Diffusion LLC is the accounting acquirer. Accordingly, 2016 results include the combined company after the merger, while 2015 comparative results reflect Diffusion LLC on a standalone basis and are not directly comparable.
The company effected a 1-for-10 reverse stock split on August 17, 2016. Share and per-share figures in the filing reflect the split. Common stock was approved for Nasdaq Capital Market listing in November 2016, after quarter-end.
Key financial metrics
| Metric | Q3 2016 / September 30, 2016 | Comparable period / prior balance |
|---|---|---|
| Revenue | No product revenue | No product revenue in Q3 2015 |
| Research and development expense | $1.94 million for Q3; $5.74 million for nine months | $0.92 million for Q3 2015; $2.60 million for nine months 2015 |
| General and administrative expense | $3.85 million for Q3; $10.07 million for nine months | $0.42 million for Q3 2015; $1.23 million for nine months 2015 |
| Net loss | $5.44 million for Q3; $15.47 million for nine months | $1.42 million for Q3 2015; $4.00 million for nine months 2015 |
| Loss per share, basic and diluted | $0.53 for Q3; $1.52 for nine months | $0.64 for Q3 2015; $1.81 for nine months 2015 |
| Cash and cash equivalents | $3.02 million | $2.00 million at December 31, 2015 |
| Working capital | Deficit of $0.39 million | $0.57 million at December 31, 2015 |
| Convertible debt principal | $2.43 million: $1.88 million current and $0.55 million noncurrent | Fair value of outstanding notes reported as approximately $5.95 million |
| Total assets / total liabilities | $19.05 million / $7.56 million | At September 30, 2016 |
No meaningful operating margin is reported because the company had no product revenue. Operating cash outflow was $9.35 million for the first nine months of 2016, compared with $2.92 million in 2015. Investing activities provided $8.50 million, primarily cash received in the merger; financing provided $1.88 million from convertible notes. Cash increased by $1.02 million during the period.
Material changes and unusual items
- Nine-month R&D expense rose by $3.14 million year over year, including costs associated with the TSC pancreatic cancer program and increased GBM drug-manufacturing costs, as well as the RES-440 impairment.
- Nine-month G&A expense rose by $8.84 million. The company cited merger costs, public-company and advisory fees, higher staffing costs, and a $2.5 million litigation-settlement charge.
- The company abandoned development of RES-440 in August 2016 and recorded an approximately $0.95 million net impairment charge. It also recognized a $0.36 million income tax benefit related to the impairment; the contingent value rights tied to RES-440 were remeasured to zero.
- The September settlement of a former Diffusion LLC member’s lawsuit included issuance of $1.88 million in one-year convertible notes bearing 6% interest, convertible at $3.50 per share. The notes were issued for cash, and the company recorded a $2.5 million settlement expense based on the estimated fair value of the notes versus cash received.
- At September 30, 2016, 10.35 million common shares were outstanding. The filing also reports 2.01 million options and 0.46 million warrants outstanding; potential shares were excluded from diluted loss per share as anti-dilutive.
Outlook, risks and contingencies
- Management estimated that September 30 cash would fund operations into the early first quarter of 2017. The company said substantial additional financing is required and disclosed no commitment for future funding. If financing is unavailable, it may delay, reduce, or stop programs, seek collaborators or strategic alternatives, or cease operations.
- The company expected expenses to increase as it advanced TSC. It anticipated entering a Phase III study in newly diagnosed GBM and potentially a Phase II pancreatic cancer study within the next 12 months, subject to available financial resources. The FDA had agreed on the design of a single 400-patient pivotal Phase III GBM study, according to management.
- The RES-529 intangible asset was carried at $8.64 million. Management stated that a future impairment could reduce or eliminate its carrying value, potentially resulting in a pretax charge up to that amount.
- A former CEO’s arbitration matter remained unresolved; management said it could not predict the outcome or possible loss and noted the matter could materially affect financial position depending on resolution. Management stated that other pending or threatened legal matters were not expected to materially affect results, financial position, or cash flows.
- Management reported disclosure controls and procedures were effective as of quarter-end. Integration of the former private company’s processes and internal controls was ongoing.
Important facts for investors to verify
- Whether the company secured sufficient financing beyond the stated early-Q1 2017 cash runway, and the resulting dilution or other financing terms.
- Timing, funding, regulatory requirements, and execution of the planned TSC GBM Phase III and potential pancreatic cancer Phase II programs.
- Progress and impairment assumptions for the $8.64 million RES-529 asset.
- Current status and potential financial exposure of the former CEO arbitration and any other material legal contingencies.
- Reconciliation of the convertible notes’ $2.43 million principal balance with the filing’s approximately $5.95 million estimated fair value, including valuation assumptions.